ArticleTransplant international : official journal of the European Society for Organ Transplantation2026
Exploring Disease-Specific Waitlist Outcomes in Simultaneous Liver-Kidney Transplantation.
Article in Transplant international : official journal of the European Society for Organ Transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current allocation system does not account for liver etiology in simultaneous liver-kidney transplantation (SLKT). This study aims to assess differences in waitlist outcomes among major liver disease groups (alcohol-related liver disease [ALD], metabolic dysfunction-associated steatohepatitis [MASH], hepatitis C virus infection, and biliary diseases) in SLKT using Organ Procurement and Transplantation Network (OPTN) registry. In total, 4,846 adult SLKT candidates listed between January 2018 and March 2024 were enrolled. Patients with MASH had worse waitlist 1-year mortality compared to ALD adjusted for patient characteristics at listing (HR 1.300, 95% CI 1.059-1.597, p = 0.012), whereas the 1-year SLKT probability was comparable. When patients were categorized by MELD score at listing (6-20, 21-29, and ≥30), patients with MASH had significantly higher 1-year waitlist mortality compared to those with ALD in the middle MELD score group (HR 1.365, 95% CI 1.008-1.834, p = 0.044). Prior to the allocation policy change in 2020, patients with MASH experienced higher waitlist mortality compared to ALD, however, this disparity was not observed following the policy change. Waitlist outcomes varied significantly depending on the etiology in SLKT. The revised 2020 allocation policy may be temporally associated with changes in mortality disparities across different liver etiologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.